Differential inhibition of transmembrane 4 L six family member 5 (TM4SF5)-mediated tumorigenesis by TSAHC and sorafenib
- PMID: 21099346
- DOI: 10.4161/cbt.11.3.14099
Differential inhibition of transmembrane 4 L six family member 5 (TM4SF5)-mediated tumorigenesis by TSAHC and sorafenib
Abstract
Two separate clinical studies of advanced hepatocarcinoma patients recently reported that the multikinase inhibitor sorafenib (nexavar) could extend survival of the patients only by 2-3 months. We also previously demonstrated that 4'-(p-toluenesulfonylamido)-4-hydroxychalcone (TSAHC) blocks the multilayer growth and migration mediated by TM4SF5, which is highly expressed in approximately 80% of Korean hepatocarcinoma patients. Therefore, we wondered how TSAHC might be different from sorafenib to deal with hepatocarcinoma in terms of the therapeutic characteristics including specificity for TM4SF5. TM4SF5 is previously shown to mediate tumorigenesis through cytosolic p27Kip1-mediated inactivation of RhoA, epithelial-mesenchymal transition, multilayer growth, migration, invasion, and tumor angiogenesis. In this study, TSAHC and two derivatives showed similar antagonistic activities against TM4SF5-mediated signaling and multilayer growth in vitro and anti-tumorigenic activity even in early stages of TM4SF5-mediated tumor formation in nude mice. Meanwhile, sorafenib was only effective much later in tumorigenesis in vivo and affected in vitro proliferation in a TM4SF5-independent manner. Altogether, these observations suggest that TSAHC may be a promising anti-tumorigenic reagent, especially against TM4SF5-mediated hepatocarcinoma.
Similar articles
-
Blockade of four-transmembrane L6 family member 5 (TM4SF5)-mediated tumorigenicity in hepatocytes by a synthetic chalcone derivative.Hepatology. 2009 Apr;49(4):1316-25. doi: 10.1002/hep.22777. Hepatology. 2009. PMID: 19177595
-
Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.Int J Cancer. 2012 Aug 1;131(3):548-57. doi: 10.1002/ijc.26374. Epub 2011 Sep 12. Int J Cancer. 2012. PMID: 21858812
-
Transmembrane 4 L six family member 5 (TM4SF5) enhances migration and invasion of hepatocytes for effective metastasis.J Cell Biochem. 2010 Sep 1;111(1):59-66. doi: 10.1002/jcb.22662. J Cell Biochem. 2010. PMID: 20506553
-
Modulation of signaling between TM4SF5 and integrins in tumor microenvironment.Front Biosci (Landmark Ed). 2011 Jan 1;16(5):1752-8. doi: 10.2741/3818. Front Biosci (Landmark Ed). 2011. PMID: 21196261 Review.
-
Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development.Curr Med Chem. 2012;19(7):938-44. doi: 10.2174/092986712799320736. Curr Med Chem. 2012. PMID: 22214462 Review.
Cited by
-
Anti-cancer Activity of Novel TM4SF5-Targeting Antibodies through TM4SF5 Neutralization and Immune Cell-Mediated Cytotoxicity.Theranostics. 2017 Jan 11;7(3):594-613. doi: 10.7150/thno.15629. eCollection 2017. Theranostics. 2017. PMID: 28255353 Free PMC article.
-
Antiangiogenic Effect of Flavonoids and Chalcones: An Update.Int J Mol Sci. 2017 Dec 22;19(1):27. doi: 10.3390/ijms19010027. Int J Mol Sci. 2017. PMID: 29271940 Free PMC article. Review.
-
Flavonoids with Anti-Angiogenesis Function in Cancer.Molecules. 2024 Mar 31;29(7):1570. doi: 10.3390/molecules29071570. Molecules. 2024. PMID: 38611849 Free PMC article. Review.
-
Therapeutic effects of TM4SF5-targeting chimeric and humanized monoclonal antibodies in hepatocellular and colon cancer models.Mol Ther Oncolytics. 2022 Jan 31;24:452-466. doi: 10.1016/j.omto.2022.01.006. eCollection 2022 Mar 17. Mol Ther Oncolytics. 2022. PMID: 35211652 Free PMC article.
-
Three Members of Transmembrane-4-Superfamily, TM4SF1, TM4SF4, and TM4SF5, as Emerging Anticancer Molecular Targets against Cancer Phenotypes and Chemoresistance.Pharmaceuticals (Basel). 2023 Jan 11;16(1):110. doi: 10.3390/ph16010110. Pharmaceuticals (Basel). 2023. PMID: 36678607 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical